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Abstract
The SWI/SNF chromatin-remodeling complex regulates gene expression and alters chromatin
structures in an ATP-dependent manner. Recent sequencing efforts have shown mutations in
BRG1 (SMARCA4), one of two mutually exclusive ATPase subunits in the complex, in a
significant number of human lung tumor cell lines and primary non-small cell lung carcinoma
(NSCLC) clinical specimens. To determine how BRG1 loss fuels tumor progression in NSCLC,
molecular profiling was performed after restoration of BRG1 expression or treatment with an
HDAC inhibitor or a DNMT inhibitor in a BRG1-deficient NSCLC cells. Importantly, validation
studies from multiple cell lines revealed that BRG1 re-expression led to substantial changes in the
expression of CDH1, CDH3, EHF and RRAD that commonly undergo silencing by other
epigenetic mechanisms during NSCLC development. Furthermore, treatment with DNMT
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inhibitors did not restore expression of these transcripts indicating that this common mechanism of
gene silencing did not account for their loss of expression. Collectively, BRG1 loss is an important
mechanism for the epigenetic silencing of target genes during NSCLC development.
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Implications
Inactivation of the SWI/SNF complex provides a novel mechanism to induce gene silencing
during NSCLC development.
Introduction
Lung and bronchus carcinoma remain two of the most lethal cancers in the United States
with over 90% of affected individuals succumbing to this disease. Over 85% of these
cancers will be classified as non-small cell lung carcinoma (NSCLC) making them the
primary clinical focus. For many cancers, treatments for early stage tumors have proven
effective while metastatic disease often carries a very poor prognosis (most patients with
metastatic lung carcinoma show an overall survival rate of <5% at 5 years). During the last
25 years, investigators have identified many of the genetic changes underlying the
appearance of NSCLC including mutations of BRAF, KRAS, EGFR, FHIT, HER2/NEU, RB,
p16INK4A, and p53 (1, 2). In addition, epigenetic silencing of the p16INK4A and CDH1 also
plays a role (3). A study demonstrating the poor survival of patients with 4 epigenetically
silenced genes further emphasizes the importance of understanding the contribution of
epigenetic mechanisms to NSCLC development (4).
Recent next generation sequencing studies have shown that mutations in components of the
SWI/SNF complex occur frequently in NSCLC samples (5). This complex, first discovered
in S. cerevisiae, shows strong conservation from yeast to Drosophila to mammals and
contains approximately 10–12 components (6, 7). The complex contains only one of the two
mutually exclusive ATPases, BRG1/SMARCA4 or BRM/SMARCA2, to fuel its remodeling
activity (8). Perturbation of chromatin remodeling is an emerging theme in cancer
progression as evidenced by the discovery of mutations in multiple members of the complex
in human cancers including NSCLC, malignant rhabdoid tumors, ovarian carcinomas and
renal cell carcinomas (8–14). In NSCLC, mutations often arise in one of the genes coding
for the ATPase component that fuels the complex, BRG1/SMARCA4 (15, 16). However,
how mutational inactivation of this gene contributes to NSCLC progression remains an open
question.
We have previously shown that re-expression of BRG1 in human cell lines lacking
expression of both mutually exclusive ATPases, BRG1 and BRM/SMARCA2, induces
expression of genes often associated with epigenetic silencing (17–20). We also observed
some overlap between genes activated by BRG1 expression and those activated by treatment
with the DNA methyltransferase (DNMT) inhibitor 5dAzaC (17). However, we did not
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assess the effects of histone acetylation in this study, another mechanism for gene silencing
(21). Because we only examined a limited number of genes, we could not determine how
commonly genes activated by BRG1 expression overlapped with those induced by DNMT
inhibition or by HDAC inhibition.
To address the question of how BRG1 inactivation contributes to NSCLC development, we
carried out a gene expression array analysis on a BRG1/BRM-deficient cell line treated with
a DNMT inhibitor, a HDAC inhibitor or infected with an adenovirus expressing BRG1. An
analysis of the results showed that BRG1 re-expression activated a greater number of genes
than either chemical reagent. Furthermore, the number of genes activated by both BRG1 and
HDAC inhibition was greater than the number induced by both BRG1 and DNMT
inhibition. We also did not observe global changes in DNA methylation patterns after BRG1
re-expression. Therefore, it appears that BRG1 loss contributes to gene silencing during
NSCLC development via a mechanism independent of changes in DNA methylation. We
also identified several important cancer-associated genes that may represent key
downstream targets for SWI/SNF complex activity. These findings provide further insight
into the role of aberrant SWI/SNF complex activity during NSCLC progression as well as
opening new avenues for treatment of the patients.
Material and Methods
Cell culture
The human NSCLC cell lines H460, H522 and A427 and the human adrenal carcinoma cell
line SWI3 were obtained from the ATCC and were grown in RPMI1640 with 10% FBS
(Gibco, Life Technologies). All experiments were performed with cell lines within 20
passages of receipt (<3 months) to ensure the identity of each cell line. For BRG1 re-
expression, we used an adenovirus expressing BRG1 and GFP, kindly provided by Dr.
Bremner, Toronto Western Research Institute (22, 23). As a control we used an adenovirus
expressing GFP alone provided by the UNC Vector Core Facility, (24). Adenovirus
infection followed our previously published protocol (24).
Microarray analyses
Total RNA was extracted from H522 cells either untreated or treated with vehicle, dimethyl
sulfoxide (DMSO), 5µM 5-aza-2'-deoxycytidine (5dAzaC), 100nM Trichostatin A (TSA) or
infected with adenovirus expressing GFP-tagged BRG1 or GFP alone for 48 hours. RNA
was labeled with Cy3 (treated or infected) and Cy5 (untreated) and hybridized to 4×44
whole human genome microarrays (cat#G4112F, Agilent Technologies, Wilmington,
Delaware, USA) by the UNC Lineberger Genomics Core for Agilent microarray analysis.
After acquiring the raw images from the Agilent Microarray Scanner with SureScan
Technology (Agilent Technologies), the raw data from captured image files was extracted
using Agilent Extraction Software (Agilent Technologies) and uploaded into UNC
Microarray Database (UMD). The normexp background correction and loess normalization
procedures were applied to the probe-level data (25). Expression measurements for each
gene were calculated by computing the mean of the normalized intensity values for all
probes mapping to that gene, as specified in a gene annotation database. This produced
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expression values for 19,749 genes. These data are available at GEO (http://
www.ncbi.nlm.nih.gov/geo/), under accession number GSE54033.
The SAMR package was used to detect differentially expressed genes by comparing the
expression values in the 5dAzaC-treated and TSA-treated cells to the expression values in
the DMSO treated cells, while Ad-BRG1-GFP infected cells were compared to Ad-GFP
infected cells in an effort to isolate the effect of BRG1 re-expression. (26). Gene expression
values were first standardized within each array. For each of the above comparisons, we
then identified differentially expressed genes using a median FDR threshold of .001. R
2.15.1 (27) was used to perform statistical analyses as well as create gene expression
heatmaps and Venn diagrams using the gplots and VennDiagram packages, respectively (28,
29).
Gene transfection
For validation studies, we carried out transient transfections using either Fugene 6
(Promega) or Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instructions.
Either the pBJ5-BRG1 plasmid expressing BRG1 or the empty vector pcDNA was
transfected to each plate, and the cells were harvested for both RNA and protein 48 hours
post-transfection as previously described (30).
Immunoblotting
Immunoblotting was performed as previously described (31). Protein lysates were subjected
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to PVDF. The membrane was incubated in blocking buffer and then with a primary antibody
overnight at 4°C. After washing, the membrane was incubated with an HRP-conjugated
secondary antibody in blocking buffer. The primary antibodies included: BRG1
(A300-813A, Bethyl laboratories), CDH1 (610281, BD Transduction Laboratories), CDH3
(2130, Cell Signaling technology), CD44 (Dr. Larry Sherman, Oregon Health Sciences
University), CK18 (DC-10, SCBT), RRAD (Dr. C. Ronald Kahn, Joslin Diabetes Center and
Harvard Medical School), and β-ACTIN (A2066, Sigma). Proteins of interest were
visualized with ECL Western blotting substrate (GE Healthcare) or a CCD camera imaging
system (ChemiDoc™ XRS+, BIO-RAD).
Quantitative RT-PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen) according to manufacturer’s
protocol, and was quantified by nanodrop spectrophotometry. 1 µg was used for cDNA
synthesis and reverse transcription was performed using M-MLV reverse transcriptase
(Invitrogen) with random primers (Invitrogen) and dNTP mix according to manufacturer’s
instructions. We determined the amount of cDNA using ABI 7900HT sequence detection
system (Applied Biosystems) with TaqMan Universal PCR Master Mix reagents and relative
quantification was analyzed by the 2−ΔΔCt method with β-actin as an endogenous control.
The primers used to detect the expression of CDH1 (Hs00170423_m1), CDH3
(Hs00354998_m1), RRAD (Hs00188163_m1), EHF (Hs00171917_m1), CD44
(Hs01075861_m1), SMARCA4 (Hs00946396_m1) and β-ACTIN (Hs01060665_g1) were
purchased from Life Technologies.
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Restriction Genomic Landscape Scanning (RGLS)
We used the RLGS technique as previously described (32, 33). Briefly, 48 hours after
transfection with empty vector or pBJ5-BRG1 into H522 or A427, cells were harvested for
high molecular weight genomic DNA using Proteinase K digestion followed by phenol
chloroform extraction and ethanol precipitation as previously described (34). DNA was
digested with NotI and EcoRV for first dimension separation followed by in-gel HinfI
digestion prior to second dimension separation, and ~2000 sites visually compared.
Differential methylation was detected by either the absence or decrease in signal intensity
(>50%). Each gel is internally controlled for successful restriction digests. In an incomplete
digest, the strong RLGS spots representing rDNA sequences would show a laddering
pattern. Those spots are only present if all restriction digests worked.
Genome-wide DNA methylation data
Dr. David Shames and Dr. Pan Du (Genentech) kindly provided genome-wide DNA
methylation data for the H522 and A427 cell lines that was obtained using the Illumina
HumanMethylation450 platform (35). Beta values ranging from 0 (lowest) to 1 (highest)
measured DNA methylation levels at over 485,000 sites across the genome.
Results
Re-expression of BRG1 and BRM in BRG1/BRM-deficient NSCLC cell lines leads to re-
expression of epigenetically silenced genes
We have previously shown that cell lines and genetically engineered mice lacking functional
BRG1 or BRM do not express the CD44 transmembrane glycoprotein, a cell adhesion
protein which can be epigenetically silenced in some human tumors (18–20, 36). When we
transfected these cells with BRG1 or BRM or treated with a DNA demethylating agent, 5-d-
Azacytidine (5-dAzaC), we observed induction of endogenous CD44 transcription (17–20).
These initial results suggested that restoration of SWI/SNF complex activity in deficient
human tumor cells might reactivate expression of epigenetically silenced genes by affecting
DNA methylation. Therefore, we checked whether another gene that commonly undergoes
epigenetic silencing in human cancer, CDH1 or E-CADHERIN, behaved in a similar fashion
to CD44. As shown in Figure 1, either treatment with TSA or 5-dAzaC or re-expression with
BRG1 or BRM induced expression of CDH1 protein in 2 BRG1/BRM-negative cell lines,
SW13, derived from an adrenal carcinoma and H522, derived from a NSCLC. In contrast,
treatment with a dominant-negative form of BRG1 (DNBRG1) that lacks ATPase or with
vehicle (DMSO) had no effect.
Analysis of BRG1 re-expression on gene expression in the H522 NSCLC cell line
To further address the relationships among BRG1 re-expression, DNA methylation and
histone acetylation, we carried out a gene expression array analysis on the BRG1/BRM-
deficient human H522 NSCLC cell line after infection with Ad-BRG1-GFP or Ad-GFP or
treatment with vehicle (DMSO), 5µM 5-dAzaC or 100nM TSA. For this analysis, we used
5µM 5-dAzaC to avoid toxicity problems we observed after treatment with 50µM. Similarly,
we did not observe toxicity with BRG1 re-expression or 100nM TSA as previously reported
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(18, 37–43). All cells were treated or infected for 48 hours. After hybridization to Agilent
whole human genome microarrays, the data was processed as described in the Material and
Methods. Expression data for a total of 19,749 genes was available for analysis.
We first analyzed these data by hierarchically clustering both the genes and the arrays in the
expression data and then creating a heat map to look for common patterns of gene
expression. As shown in Figure 2, the 4 replicates from each treatment group clustered
together, which shows consistency of gene expression patterns among the replicates. Of
interest, the groups infected with adenovirus showed greater similarity to each other than to
either TSA or 5-dAzaC treatments. It also appeared that infection with Ad-GFP alone
caused unique changes in gene expression compared to the other treatment groups.
Furthermore, the DMSO treatment control showed the least similarity to any of the other
treatment groups while TSA and 5-dAzaC treatments showed the most similarity. Therefore,
for gene expression altered by TSA or 5-dAzaC treatments, we searched for differential
expression between each treatment group and the DMSO treated cells. We identified genes
whose expression was induced by BRG1 re-expression by comparing the Ad-BRG1-GFP
infection to the Ad-GFP infection.
We first looked for genes that showed changed expression after Ad-BRG1 infection. Our
results found expression levels for 5527 genes increased and 6510 decreased after BRG1-
GFP re-expression normalized to GFP expression alone (Supplemental Table 1). However,
this number represents an over estimation because some genes showed decreased expression
under all treatment conditions (Supplemental Table 1). In a similar vein, expression of 2436
genes increased and 2763 genes decreased after 5-dAzaC treatment (Supplemental Table 2).
In contrast, we observed fewer changes in gene expression after TSA treatment, where 560
genes went up and 995 genes went down (Supplemental Table 3).
We also identified genes whose expression increased after 2 different treatments. We
observed 429 genes that showed increased expression after either 5-dAzaC treatment or
BRG1 re-expression (Supplemental Table 4). However, to be conservative in these analyses,
we first focused only on those genes whose expression increased >2 fold compared to the
parental cell line. Of these 429 genes, Table 1 lists the 145 genes that increased more than 2
fold after BRG1 re-expression including genes such as CDH3 and GDF15 that are
associated with human tumor development (44, 45). Interestingly, GDF15 was previously
reported to undergo silencing by histone acetylation (46). In a similar analysis for genes
whose expression increased after TSA treatment or BRG1 re-expression, we found 186
genes (Supplemental Table 5). Of 140 genes from this group that went up by more than 2-
fold after BRG1 re-expression, CDH1 showed the most robust increase in expression while
CD44, KRT4, KRT8 and KRT18 also showed strong induction (Table 2). Finally, we looked
for genes whose expression went up under all three conditions. This group contained the
fewest genes (86), of which 55 genes increased by more than 2 fold after BRG1 re-
expression (Table 3, Supplemental Table 6). Interestingly, GADD45A, a stress responsive
gene, showed strong induction under all 3 conditions (Supplemental Table 6) (47). Finally,
we identified genes that showed increased expression after TSA or 5-dAzaC treatment but
not BRG1 (Supplemental Table 7). We found 170 genes, of which 148 increased by at least
2-fold after TSA treatment. These results are summarized in a Venn diagram in Figure 2B.
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Validation of gene expression array data
One caveat from studies using adenovirus infection to express proteins is the significant
production of protein by the adenovirus infection. To address this issue, we re-expressed
BRG1 in the H522 cell line by gene transfection to minimize overexpression. We also
included a second BRG1/BRM-deficient NSCLC cell line, A427, where we have previously
shown induction of CD44 after BRG1 expression (20). We examined expression of CDH1,
CD44 and CK18, as well as potentially novel BRG1 regulated genes, CDH3, EHF and
RRAD. A previous report showed that RRAD, a member of the RAS superfamily, is
epigenetically silenced by DNA methylation in a large percentage of NSCLC while EHF, a
member of the ETS transcription factor family, is silenced in prostate cancer (48, 49). CDH3
(P-cadherin) maps next to CDH1 and can also undergo silencing during human tumor
development (45).
As shown in Figure 1B, we observed increased expression of these genes in H522 consistent
with microarray data. However, we found increases only in CD44, EHF and RRAD
expression after BRG1 re-expression in the A427 cell line, indicating differences between
these 2 NSCLC cell lines. We also assessed protein expression by Western blot analysis for
genes with available antibodies (Figure 1C). The Western blot data in Figure 1C
recapitulates the qPCR data in panel B i.e. a more robust induction of target protein
expression with BRG1 in the H522 cell line versus the A427 cell line (notice the ratio of
protein expression to the β-ACTIN control in the 2 cell lines). Thus, the Western blot results
appeared consistent with the qPCR findings.
Gene expression changes after BRG1 re-expression in BRG1/BRM-deficient NSCLC cells
does not correlate with DNA methylation levels
To further investigate the relationship between BRG1 loss and DNA methylation, we asked
whether BRG1 re-expression altered DNA methylation in NSCLC cell lines. We used
restriction landmark genomic scanning (RLGS) to detect DNA methylation changes in the 2
BRG1/BRM-deficient NSCLC cell lines after BRG1 re-expression (32, 33). RLGS uses
two-dimensional gel electrophoresis system to detect radiolabeled methylation sensitive
restriction endonuclease sites and create “landmarks” seen on the resulting autoradiograph.
This approach has been successfully used to detect changes in DNA methylation in primary
NSCLC samples (50). We first demonstrated that our treatment conditions with 5-dAzaC led
to re-expression of methylation-silenced CDH1 in the H460 NSCLC cell line as previously
reported (Figure 3A)(51). In contrast, only treatment with TSA +/− 5-dAzaC or infection
with Ad-BRG1 led to CDH1 and CD44 expression in H522 cells, in agreement with the
gene expression array results (Figure 3A).
RLGS analysis of H522 cells transfected with vector or BRG1 revealed only three
prominent landmarks that appeared after BRG1 re-expression (Figure 3B). However,
sequencing of these DNAs revealed that they originated from the BRG1 transgene and not
from changes in methylation of the H522 cellular DNA. Similar results were observed for
the A427 cell line (Supplementary Figure 1). We could not detect any additional changes
after BRG1 re-expression. Therefore, this “snapshot” of global DNA methylation did not
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show major changes after BRG1 re-expression. We cannot, off course, exclude that DNA
methylation changes below the detection limit of about 5% change occurred.
Finally, we examined whether the DNA methylation status of these genes would predict
their response to BRG1 re-expression i.e. do high levels of DNA methylation inhibit the
effects of BRG1 re-expression? To address this issue, we took advantage of a recent study
that used DNA methylation arrays to compare the patterns among 69 human NSCLC cell
lines including H522 and A427 (35). We compared the methylation patterns on 4 genes that
showed increased expression in one or both cell lines, CD44, CDH1, RRAD and CDH3. As
shown in Figure 4, A427 cells displayed significantly more DNA methylation along the
length of the CD44 gene than H522 cells. However, BRG1 re-expression induced CD44
expression only in the A427 cell line (Figure 1B). In contrast, H522 cells showed
significantly less methylation in the promoter region of CDH3 than A427 cells, consistent
with BRG1 re-expression inducing its expression in H522 alone. Furthermore, RRAD basal
expression was higher in A427 cells despite the presence of significantly more DNA
methylation along the entire promoter and coding region. Similarly, we did not observe an
association between CDH1 methylation and expression. Taken together, our results support
the notion that DNA methylation correlates poorly with altered gene expression after BRG1
re-expression.
Discussion
Epigenetic alterations are generally accepted as critical components of neoplastic
transformation (52, 53). Most studies have focused upon the mechanisms of DNA
methylation and histone modifications as inducers of gene silencing. In this study, we
provide evidence that loss of SWI/SNF complex activity via mutations in the ATPase
components may provide another mechanism for gene silencing during lung tumor
development. This role for aberrant SWI/SNF complex activity may account for the
significant number of mutations found in most of the subunits across a large number of
human tumors (5, 14)
How could decreased expression or loss of SWI/SNF complex activity lead to changes in
gene expression? One potential mechanism could involve altered activity of transcription
factors associated with the SWI/SNF complex. Previous studies have shown interactions
between various SWI/SNF complex members and transcription factors including c-MYC,
NRF2, p53 and NFkB (54–57). These studies also established that loss of BRG1 or SNF5
altered downstream signaling of these transcription factors. Several recent reports have also
demonstrated global changes in nucleosome positioning after loss of BRG1 expression (55,
58, 59). Therefore, alterations in SWI/SNF complex activity could affect gene expression by
either causing nucleosome positioning changes at gene promoters or at transcription factor
binding sites.
Our studies also showed that treatment with a HDAC inhibitor or re-expression of BRG1
could increase expression of several genes frequently silenced in NSCLC, such as CDH1
and CD44. This brings up the possibility that loss of BRG1 and BRM proteins, the critical
ATPase subunits of the SWI/SNF complex, could influence gene silencing by affecting the
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activity of other histone or chromatin modifying complexes. Multiple examples exist in the
literature illustrating the interdependence between components of the SWI/SNF complex
and other chromatin remodeling complexes (60, 61). Thus, loss of SWI/SNF complex
activity could lead to gene silencing through the repressive effects of other complexes such
as the ISWI or polycomb complexes.
The SWI/SNF complex can also associate with different histone-modifying enzymes. The
SWI/SNF complex cooperates with histone acetyl transferases to promote epigenetic marks
at histones (62, 63). Therefore, loss of SWI/SNF complex activity could also lead to loss of
histone acetylation marks in tumor cells. In the NUMAC complex (nucleosomal methylation
activation complex), members of the SWI/SNF complex including BRG1 interact with the
co-activator-associated arginine methyltransferase-1 (CARM1) to regulate activity for
histone methylation (64). This again provides another mechanism where loss of SWI/SNF
complex function could potentially lead to loss of activating marks on histones. The
SWI/SNF complex also cooperates with other histone-modifying enzymes such as histone
deacetylases-3 (HDAC3) and the transcriptional co-repressors KAP-1 (Krab associated
protein 1) within the NCoR-1 (Nuclear receptor corepressors-1) complex (65). Therefore,
loss of BRG1 and BRM could alter their activities by potentially increasing their repression
of gene transcription.
Although existing next generation sequencing studies have found a significant number of
BRG1 mutations and deletion in squamous cell and adenocarcinomas of the lung, their
effects on SWI/SNF complex activities remain unknown. Many of the mutations result in
truncated forms of BRG1 that appear to be degraded (11, 18). However, in these cohorts,
five of eight mutations in squamous cell and ten out of twenty mutations in
adenocarcinomas are missense. Therefore, determining the effects of these single amino
acids changes on protein function becomes imperative. Importantly, several recent reports
have shown that missense mutations in BRG1 can dramatically alter its biological activity
(30, 66). Whether these BRG1 mutant proteins can also result in gene silencing remains an
important unanswered question.
Our current study implicates BRG1 loss as another route for epigenetic silencing during
NSCLC development. The large number of changes in gene expression associated with
BRG1 re-expression compared to treatment with a DNMT or HDAC inhibitor appears
consistent with this notion. While the mechanism for this effect requires further study,
experiments identifying changes in BRG1 binding sites by ChIP-seq and nucleosome
positioning by MNase-seq should help resolve this issue. Furthermore, the validation of
additional BRG1 target genes should lead to the generation of new treatment approaches for
individuals with BRG1-deficient NSCLC. Our results also strongly suggest that treatment
with DNMT or HDAC inhibitors may not prove efficacious in patients with BRG1-deficit
NSCLC. The cell lines developed in this study as well as genetically-engineered mouse
models for BRG1-induced tumor development will accelerate the translation of future
treatment options into clinical practice (67, 68).
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Figure 1. Re-expression of silenced genes in BRG1/BRM-deficient cell lines
(A) SW13 or H522 cells were either treated with 5-dAzaC and/or TSA or transfected with
the empty expression vector pcDNA3 or expression vectors for BRG1, DNBRG1 or BRM.
After 72 hours, protein was extracted, separated and immunoblotted for the indicated
proteins as described in the Material and Methods. β-actin served as the loading control. (B)
& (C) H522 and A427 cells were transfected with BRG1 (pBJ5-BRG1) or empty vector
(pcDNA3). After 48 hours, cells were harvested for either total RNA or protein. Gene
expression was then evaluated by qPCR using ABI primers (B) or by western blotting (C).
For qPCR, expression for each gene was normalized to β-actin levels; for western blotting,
β-actin served as a loading control. * means P-value< 0.05, and error bars represent +S.E.M.
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Figure 2. Characterization of gene expression changes in H522 NSCLC cells
Gene expression analysis using array technology was carried out as described in the Material
and Methods. (A) Heatmap of gene expression data in H522 NSCLC cells after
standardizing expression values within arrays, median centering within each gene and
hierarchically clustering both genes and arrays (gene dendrogram not displayed). Expression
values for 19,749 genes are shown. (B) Venn diagram displaying counts of differentially up-
regulated genes according to the comparison groups described in the Material and Methods.
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Figure 3. Changes in DNA methylation does not account for gene expression changes after BRG1
re-expression in H522 and A427 cells
(A) H522 cells were infected with adenovirus expressing human BRG1 and/or GFP as
described in the Material and Methods. H522 and H460 cells were treated with DMSO, 5µM
5-dAzaC or 100nM TSA as described in the Material and Methods. After 48 hours, dishes
were harvested for total protein. Expression of CDH1, CD44 and CK18 was then measured
by Western blotting. β-actin served as a loading control and the H460 cell line served as a
positive control for 5-dAzaC treatment (51). (B) H522 cells were transfected with BRG1
(pBJ5-BRG1) or empty vector (pcDNA3). After 48 hours, cells were harvested for DNA and
used for RLGS as described in the Material and Methods.
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Figure 4. DNA methylation does not correlate with gene expression changes after BRG1 re-
expression in H522 and A427 cells
Beta values ranging from 0 (lowest) to 1 (highest) show DNA methylation levels at sites
across four representative BRG1 target genes, CD44, CDH1, RRAD, and CDH3, for both
H522 and A427 cell lines. Methylation levels are coded as follows: low (green, beta < 0.3),
intermediate (white, 0.3 < beta < 0.7), high (red, beta > 0.7).
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Table 1
Genes up-regulated by both 5-dAzaC treatment and BRG1 re-expression
Differentially expressed genes were identified, as described in Material and Methods. Of the 429 genes up-
regulated in both 5-dAzaC treatment vs. DMSO and BRG1-GFP re-expression vs. GFP, the 145 genes that
increased more than two fold after BRG1 re-expression are shown.
ABCG4 GALNAC4S-6ST MAPKAPK3 SESN2
ABHD11 GALNTL4 MCFD2 SHC2
AIM1L GCC1 METRNL SLC1A4
AKAP8 GDF15 MGLL SMOX
APLN GJB2 MMP1 SPEG
ARHGAP22 GOT1 MMP19 STC2
ARHGEF3 GPIHBP1 MORC4 STX4
ASB2 GPN1 MPPED1 TCF7
ATP6V1D GPRIN2 MRPL18 TICAM1
BLCAP GPT2 MSI2 TMEM130
BMP5 GRB10 MT1E TMEM198
C10orf49 GUCA1B MYLK2 TNFRSF10B
C15orf52 HIVEP3 MYO5B TNFRSF8
C18orf25 HMGCS1 NEFM TNNC2
C21orf34 HSPA4 NPPB TPD52L1
C6orf145 HSPH1 NR3C1 TPRXL
C7orf29 IDH1 NUPR1 TRIP6
CABLES1 IFFO2 OGDHL TSSC4
CAMK2N1 IFRD1 OR3A3 UPP1
CARD10 IL11 P2RY2 VDR
CBS IL17D PCBP4 WARS
CCDC130 INHBB PDZD2 YKT6
CCDC3 KCNA7 PHLDB3 ZFAND2A
CDH3 KCNQ1 PINK1 ZNF354A
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Table 2
Genes up-regulated by both TSA treatment and BRG1 re-expression
Differentially expressed genes were identified, as described in Material and Methods. Of the 186 genes up-
regulated in both TSA treatment vs. DMSO and BRG1-GFP re-expression vs. GFP, the 140 genes that
increased more than two fold after BRG1 re-expression are shown.
A4GALT ETV7 LOC149501 TBC1D9
AFAP1 F3 LOC441376 TGFA
AGPS FAM127A LOC442249 TKT
AK2P2 FAM151A LOC54492 TMEM37
AKR1C3 FAM174B LOC647954 TNNC1
ANKRD13A FAM65B MAP1B TRIM2
ARL4D FLJ40504 MAP4K4 TSPAN5
ASMTL GATA6 MYLIP TTYH1
BAMBI GDPD5 MYO10 TUBA4A
BTG2 GLDC MYO1E TUBB2A
C11orf67 GSN MYOF TUFT1
C19orf33 GUK1 NACAD TXNIP
C1orf167 HABP4 NCRNA00087 TXNRD1
C1orf226 hCG_1988300 NPPC VSTM2L
CALB2 HDAC5 NPTX2 WNT10A
CAPN2 HEATR5A OBFC2A WNT4
CCL2 HIST1H2AD OSGIN1 WNT6
CCND1 HRCT1 P4HA3 ZCCHC12
CD44 HS3ST2 PEG10 ZCCHC17


































































Song et al. Page 22
Table 3
Genes up-regulated by 5-dAzaC treatment, TSA treatment, and BRG1 re-expression
Differentially expressed genes were identified, as described in Material and Methods. Of the 86 genes up-
regulated in 5-dAzaC treatment vs. DMSO, TSA treatment vs. DMSO, and BRG1-GFP re-expression vs. GFP,
the 55 genes that increased more than two fold after BRG1 re-expression are shown.
ANKRD6 GFOD1 GLIPR2 NDRG1 RAB31
ANXA2 GFPT2 ID3 NGEF RASSF2
ATF3 DDX58 ID4 NMNAT2 RHOU
BCL6 EGR2 KIF5C OCC-1 RIPK4
BIK EMILIN2 KRT18P34 ODC1 S100A2
C16orf45 FAM89A LAMB3 PAQR9 SLC30A3
C6orf114 FEZ1 LGALS3 PEA15 SMAD3
CCK FTL LMCD1 PLCE1 SRXN1
CD83 FYN LOC26010 PODXL SULF2
CGNL1 GABARAPL1 MEG3 PPP1R14C TPM1
CHST2 GADD45A MTM1 RAB11FIP5 WWC3
Mol Cancer Res. Author manuscript; available in PMC 2015 April 01.
